The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Response to the anti-EGFR antibody panitumumab combined with standard neoadjuvant chemotherapy in triple-negative breast cancer (TNBC): The immune and IGFR pathways.
Frederique Penault-Llorca
No relevant relationships to disclose
Marie-Melanie Dauplat
No relevant relationships to disclose
Catherine Abrial
No relevant relationships to disclose
Beatrice E. Weber
No relevant relationships to disclose
Marie-Ange Mouret-Reynier
No relevant relationships to disclose
Joseph Gligorov
No relevant relationships to disclose
Olivier Tredan
No relevant relationships to disclose
Maud Privat
No relevant relationships to disclose
Nancy Uhrhammer
No relevant relationships to disclose
Alexis Desrichard
No relevant relationships to disclose
Yannick Bidet
No relevant relationships to disclose
Nina Radosevic-Robin
No relevant relationships to disclose
Anne Cayre
No relevant relationships to disclose
Cécile Aubé
No relevant relationships to disclose
Pierre Charles Romero
No relevant relationships to disclose
Fabrice Kwiatkowski
No relevant relationships to disclose
Nassera Chalabi
No relevant relationships to disclose
Yves-Jean Bignon
No relevant relationships to disclose
Philippe Chollet
No relevant relationships to disclose
Jean-Marc Nabholtz
No relevant relationships to disclose